ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) Director Elisha Finney sold 1,700 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $179.00, for a total transaction of $304,300.00. Following the completion of the transaction, the director directly owned 4,871 shares of the company’s stock, valued at approximately $871,909. This represents a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
ICU Medical Stock Performance
NASDAQ:ICUI opened at $179.27 on Monday. ICU Medical, Inc. has a 12 month low of $113.37 and a 12 month high of $192.85. The firm has a fifty day simple moving average of $163.72 and a 200-day simple moving average of $149.91. The company has a current ratio of 2.37, a quick ratio of 1.19 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $4.48 billion, a P/E ratio of 75.01, a PEG ratio of 2.26 and a beta of 0.88.
ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.30. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. The firm had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. During the same period in the previous year, the company earned $2.03 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts anticipate that ICU Medical, Inc. will post 7.22 earnings per share for the current year.
Wall Street Analysts Forecast Growth
ICUI has been the topic of several research analyst reports. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Piper Sandler increased their price objective on ICU Medical from $195.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Needham & Company LLC raised their price objective on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th. Finally, Weiss Ratings raised ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $195.20.
Get Our Latest Stock Report on ICUI
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP purchased a new stake in ICU Medical in the second quarter valued at $26,000. Global Retirement Partners LLC grew its position in ICU Medical by 203.4% during the 3rd quarter. Global Retirement Partners LLC now owns 179 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 120 shares during the period. Bessemer Group Inc. raised its stake in shares of ICU Medical by 65.8% during the 3rd quarter. Bessemer Group Inc. now owns 189 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 75 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of ICU Medical by 78.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 239 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 105 shares during the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of ICU Medical by 26.2% during the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 65 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.
About ICU Medical
ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.
Recommended Stories
- Five stocks we like better than ICU Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
